CR20160389A - Terapias dirigidas - Google Patents

Terapias dirigidas

Info

Publication number
CR20160389A
CR20160389A CR20160389A CR20160389A CR20160389A CR 20160389 A CR20160389 A CR 20160389A CR 20160389 A CR20160389 A CR 20160389A CR 20160389 A CR20160389 A CR 20160389A CR 20160389 A CR20160389 A CR 20160389A
Authority
CR
Costa Rica
Prior art keywords
methods
directed therapies
disclosure
cationic
localization
Prior art date
Application number
CR20160389A
Other languages
English (en)
Inventor
David Hung
Emma Mccullagh
Roopa Rai
Balaji Dashrath Sathe
Gonzalo Ureta
Sarvajit Chakravarty
Sebastián Bernales
Original Assignee
Medivation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies Inc filed Critical Medivation Technologies Inc
Publication of CR20160389A publication Critical patent/CR20160389A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0026—Acridine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/003—Thiazine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B17/00—Azine dyes
    • C09B17/02—Azine dyes of the benzene series

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta revelación describe composiciones y métodos para la administración y localización de agentes terapéuticos a los objetivos terapéuticos. Esta revelación también proporciona formas multivalentes de tintes catiónicos ("multímeros de tinte catiónico") y métodos por los que estos compuestos se pueden utilizar para tratar lesiones en las articulaciones.
CR20160389A 2014-01-28 2015-01-28 Terapias dirigidas CR20160389A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN258DE2014 2014-01-28
PCT/US2015/013334 WO2015116707A1 (en) 2014-01-28 2015-01-28 Targeted therapeutics

Publications (1)

Publication Number Publication Date
CR20160389A true CR20160389A (es) 2016-12-14

Family

ID=52484560

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160389A CR20160389A (es) 2014-01-28 2015-01-28 Terapias dirigidas

Country Status (14)

Country Link
US (1) US20170119907A1 (es)
EP (1) EP3099335A1 (es)
JP (1) JP2017505774A (es)
CN (1) CN106132443A (es)
AU (1) AU2015211075A1 (es)
BR (1) BR112016017493A2 (es)
CA (1) CA2938181A1 (es)
CR (1) CR20160389A (es)
IL (1) IL246956A0 (es)
MX (1) MX2016009867A (es)
NO (1) NO20161351A1 (es)
PH (1) PH12016501491A1 (es)
SG (1) SG11201606211QA (es)
WO (1) WO2015116707A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017019833A1 (en) * 2015-07-29 2017-02-02 Medivation Technologies, Inc. Compositions containing repair cells and cationic dyes
WO2017019832A1 (en) * 2015-07-29 2017-02-02 Medivation Technologies, Inc. Methods and compositions using repair cells and cationic dyes
WO2017019817A1 (en) * 2015-07-29 2017-02-02 Medivation Technologies, Inc. Methods and compositions for targeted therapeutics
WO2017019830A1 (en) * 2015-07-29 2017-02-02 Medivation Technologies, Inc. Methods and compositions for targeted therapeutics
CN110337431B (zh) * 2017-03-03 2022-08-26 日本瑞翁株式会社 二芳基胺系化合物、抗老化剂以及聚合物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6849255B2 (en) 1998-08-18 2005-02-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for enhancing cartilage repair
AU5723601A (en) 2000-04-25 2001-11-07 Osiris Therapeutics Inc Joint repair using mesenchymal stem cells
US7776567B2 (en) * 2005-03-17 2010-08-17 Biotium, Inc. Dimeric and trimeric nucleic acid dyes, and associated systems and methods
US20100278745A1 (en) * 2006-12-21 2010-11-04 Norbert Lange Compounds for fluorescence imaging

Also Published As

Publication number Publication date
AU2015211075A1 (en) 2016-09-08
BR112016017493A2 (pt) 2017-08-08
NO20161351A1 (en) 2016-08-24
EP3099335A1 (en) 2016-12-07
IL246956A0 (en) 2016-09-29
SG11201606211QA (en) 2016-09-29
US20170119907A1 (en) 2017-05-04
PH12016501491A1 (en) 2016-09-14
WO2015116707A1 (en) 2015-08-06
CN106132443A (zh) 2016-11-16
JP2017505774A (ja) 2017-02-23
MX2016009867A (es) 2017-01-11
CA2938181A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
CO2018002060A2 (es) Compuestos farmacéuticos
MX2021009673A (es) Moduladores de ror-gamma.
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
PT4122464T (pt) Combinações terapêuticas para o tratamento de doenças do fígado
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CR20160389A (es) Terapias dirigidas
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
SV2016005313A (es) Derivados de carboxamida
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
ECSP18079073A (es) Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos
DOP2017000138A (es) Derivados de fumagilol
MX394670B (es) Agentes anticancerigenos y preparacion de los mismos.
CL2017000644A1 (es) Compuestos esteroides c-20, composiciones y usos de estos para tratar lesiones cerebrales traumáticas (tbi), incluidas concusiones.
EP3880251C0 (en) FORMULATIONS OF THERAPEUTIC AGENTS AGAINST INFLUENZA
CO7020185A1 (es) Composición farmacéutica que comprende compuestos orgánicos naturales para el tratamiento de glaucoma de angulo abierto e hipertensión ocular